Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Marker Therapeutics Inc.

    NASDAQ: MRKR · Real-Time Price · USD
    1.63
    -0.06 (-3.55%)
    At close: Jun 13, 2025, 3:59 PM
    1.63
    0.00%
    After-hours: Jun 13, 2025, 05:50 PM EDT

    Marker Therapeutics Statistics

    Share Statistics

    Marker Therapeutics has 11.31M shares outstanding. The number of shares has increased by 20.07% in one year.

    Shares Outstanding

    n/a
    		 11.31M

    Shares Change (YoY)

    n/a
    		 20.07%

    Shares Change (QoQ)

    n/a
    		 0.02%

    Owned by Institutions (%)

    n/a
    		 49.73%

    Shares Floating

    n/a
    		 7.9M

    Failed to Deliver (FTD) Shares

    n/a
    		 67

    FTD / Avg. Volume

    n/a
    		 0.07%

    Short Selling Information

    The latest short interest is 118.68K, so 1.11% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 118.68K

    Short % of Shares Out

    n/a
    		 1.11%

    Short % of Float

    n/a
    		 1.44%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -2.6 and the forward PE ratio is -0.94. Marker Therapeutics's PEG ratio is 0.07.

    PE Ratio

    n/a
    		 -2.6

    Forward PE

    n/a
    		 -0.94

    PS Ratio

    n/a
    		 4.24

    Forward PS

    n/a
    		 0.1

    PB Ratio

    n/a
    		 0

    P/FCF Ratio

    n/a
    		 -2.56

    PEG Ratio

    n/a
    		 0.07
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Marker Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.36, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 6.36

    Quick Ratio

    n/a
    		 6.36

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,318,200

    Profits Per Employee

    n/a
    		 $-2,146,200

    Employee Count

    n/a
    		 5

    Asset Turnover

    n/a
    		 0.3

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 49.95K

    Effective Tax Rate

    n/a
    		 -467665.08%

    Stock Price Statistics

    The stock price has increased by -60.82% in the last 52 weeks. The beta is 1.45, so Marker Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.45

    52-Week Price Change

    n/a
    		 -60.82%

    50-Day Moving Average

    n/a
    		 1.25

    200-Day Moving Average

    n/a
    		 2.36

    Relative Strength Index (RSI)

    n/a
    		 57.4

    Average Volume (20 Days)

    n/a
    		 102,839

    Income Statement

    In the last 12 months, Marker Therapeutics had revenue of 6.59M and earned -10.73M in profits. Earnings per share was -1.19.

    Revenue

    n/a
    		 6.59M

    Gross Profit

    n/a
    		 -6.88M

    Operating Income

    n/a
    		 -11.12M

    Net Income

    n/a
    		 -10.73M

    EBITDA

    n/a
    		 -4.53M

    EBIT

    n/a
    		 -4.53M

    Earnings Per Share (EPS)

    n/a
    		 -1.19
    Full Income Statement

    Balance Sheet

    The company has 19.19M in cash and 0 in debt, giving a net cash position of 19.19M.

    Cash & Cash Equivalents

    n/a
    		 19.19M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -447.02M

    Total Assets

    n/a
    		 16.99M

    Working Capital

    n/a
    		 14.49M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -10.91M and capital expenditures 0, giving a free cash flow of -10.91M.

    Operating Cash Flow

    n/a
    		 -10.91M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -10.91M

    FCF Per Share

    n/a
    		 -1.21
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -168.69% and -162.82%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -168.69%

    Pretax Margin

    n/a
    		 -162.06%

    Profit Margin

    n/a
    		 -162.82%

    EBITDA Margin

    n/a
    		 -68.69%

    EBIT Margin

    n/a
    		 -168.68%

    FCF Margin

    n/a
    		 -165.53%

    Dividends & Yields

    MRKR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for MRKR is $12.5, which is 666.9% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $12.5

    Price Target Difference

    n/a
    		 666.9%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jan 27, 2023. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Jan 27, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 -33.99

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist